Melfalano Teva

Melphalan Hydrochloride, the active ingredient in Melfalano Teva, is an alkylating agent presented as an injectable solution for intravenous systemic use. It is employed in the treatment of various malignancies, including multiple myeloma, ovarian cancer, melanoma, neuroblastoma, and other solid tumors, by targeting rapidly dividing cancer cells.

GNH USA supplies Melfalano Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use.

Melfalano Teva (melphalan hydrochloride) is used in chemotherapy regimens for several solid tumor and hematologic malignancies.

- Multiple myeloma: incorporated into conditioning or combination protocols to achieve disease control. - Ovarian cancer: administered as part of multi‑agent chemotherapy to reduce tumor burden. - Melanoma: used in high‑dose regimens for metastatic disease management. - Neuroblastoma: employed in intensive therapy schedules for pediatric patients. - Other solid tumors: applied in various combination regimens where alkylating activity is required.

Melfalano Teva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: reduced white blood cells, red blood cells, and platelets. - Fatigue: persistent tiredness affecting daily activities. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers after treatment. - Severe infections: due to profound immunosuppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: decreased kidney function in susceptible patients. - Cardiotoxicity: rare cardiac dysfunction or arrhythmias.

Prior to initiating therapy, clinicians should assess patient-specific factors and monitor for potential complications.

- Baseline blood counts: obtain complete blood count to evaluate marrow reserve. - Renal function: assess serum creatinine and adjust dosing if necessary. - Hepatic status: monitor liver enzymes for potential toxicity. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss contraception. - Concomitant myelosuppressive agents: use with caution to prevent excessive bone‑marrow suppression. - Store at ambient temperature: keep in original container, protect from moisture and light, and do not freeze.

Melphalan may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive bone‑marrow toxicity. - Live vaccines: increased risk of infection due to immunosuppression. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Allopurinol: may increase melphalan plasma levels. - Antiemetics (e.g., ondansetron): monitor for QT prolongation. - CYP450 inducers (e.g., rifampin): possible reduction in melphalan exposure.